Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.

BMC Cancer · 2009 · PMC2719665 · PMID 19619339

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

The PFS was better, with borderline significance, in patients that received second line bevacizumab compared to those that received third or later line bevacizumab (5.0 vs. 2.4 months, hazard ratio (HR) 0.49 [95% CI, 0.23–1.05], P = 0.060); the OS was not statistically different according to the line of bevacizumab treatment (16.4 vs. 11.2 months, HR 0.67 [95% CI, 0.24–1.83], P = 0.426).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.